Hepatocellular carcinoma

Liver cancer carries a five-year survival of 21.7%,¹ and for the fifth of patients diagnosed after it has spread, 3.3%.

The best first-line therapy available reaches a median of nineteen months.²

21.7%¹

five-year survival for liver cancer

3.3%¹

for the fifth of patients diagnosed after it has spread

19²

months on the best first-line therapy available

Four large pharmaceutical companies entered this target inside eighteen months, and the first public structure appeared only in late 2025. That is a solvable problem standing between patients and a therapy.